DexCom, Inc. (NASDAQ:DXCM)‘s stock had its “hold” rating restated by equities researchers at Northland Securities in a note issued to investors on Thursday. They currently have a $50.00 price target on the medical device company’s stock. Northland Securities’ price objective would indicate a potential upside of 11.19% from the stock’s current price.

Other equities research analysts have also issued reports about the company. Oppenheimer Holdings, Inc. set a $92.00 price target on DexCom and gave the company a “buy” rating in a research report on Wednesday, August 2nd. Cowen and Company reissued a “buy” rating and issued a $90.00 price target on shares of DexCom in a research report on Friday, July 14th. BMO Capital Markets reissued a “buy” rating and issued a $105.00 price target on shares of DexCom in a research report on Thursday, July 13th. Piper Jaffray Companies reissued a “buy” rating and issued a $78.00 price target on shares of DexCom in a research report on Wednesday, July 12th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $90.00 price target on shares of DexCom in a research report on Tuesday, August 22nd. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $71.64.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.07. The business had revenue of $170.60 million during the quarter, compared to analyst estimates of $166.54 million. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. DexCom’s quarterly revenue was up 24.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.24) EPS.

WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/11/02/dexcom-inc-dxcm-receives-hold-rating-from-northland-securities.html.

In other DexCom news, EVP Richard Doubleday sold 1,635 shares of the firm’s stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of $44.82, for a total value of $73,280.70. Following the completion of the transaction, the executive vice president now owns 65,049 shares in the company, valued at approximately $2,915,496.18. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Steven Robert Pacelli sold 1,450 shares of the firm’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $69.81, for a total value of $101,224.50. The disclosure for this sale can be found here. Insiders have sold a total of 23,208 shares of company stock valued at $1,597,567 in the last quarter. 1.70% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. State of Wisconsin Investment Board boosted its stake in DexCom by 169.7% in the 3rd quarter. State of Wisconsin Investment Board now owns 184,765 shares of the medical device company’s stock worth $9,040,000 after purchasing an additional 116,254 shares during the period. State Board of Administration of Florida Retirement System boosted its stake in DexCom by 1.3% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 126,337 shares of the medical device company’s stock worth $6,181,000 after purchasing an additional 1,600 shares during the period. Frontier Capital Management Co. LLC boosted its stake in DexCom by 85.0% in the 3rd quarter. Frontier Capital Management Co. LLC now owns 848,670 shares of the medical device company’s stock worth $41,521,000 after purchasing an additional 389,947 shares during the period. Dupont Capital Management Corp boosted its stake in DexCom by 22.0% in the 3rd quarter. Dupont Capital Management Corp now owns 8,662 shares of the medical device company’s stock worth $424,000 after purchasing an additional 1,560 shares during the period. Finally, OLD National Bancorp IN boosted its stake in DexCom by 13.2% in the 3rd quarter. OLD National Bancorp IN now owns 9,966 shares of the medical device company’s stock worth $488,000 after purchasing an additional 1,163 shares during the period.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.